To interrupt M-CSF signaling we selected sunitinib, a small-molecule receptor tyrosine kinase inhibitor that is US FDA approved for pancreatic cancer, gastrointestinal stromal tumors, and renal cell carcinoma. Here, NTRK1 is linked to hereditary clear cell renal cell carcinoma.